Literature DB >> 11927494

Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students.

Long Fu Xi1, Joseph J Carter, Denise A Galloway, Jane Kuypers, James P Hughes, Shu Kuang Lee, Diane E Adam, Nancy B Kiviat, Laura A Koutsky.   

Abstract

Analogous to the epidemiology of different types of human papillomaviruses (HPVs), variants of a single type such as HPV16 may differ in the natural course of infection. A prospective study was conducted in a cohort of female university students who did not have HPV16 DNA or antibody at enrollment. Subjects were followed every 4 months with Pap smear and colposcopic examinations and tests for HPV DNA and antibody. Of 528 women, 62 acquired HPV16 infection during follow-up. The 5-year cumulative incidence was 12.6% for infection with HPV16 prototype-like variants and 3.1% for infection with non-prototype-like (NPL) variants. Among those with incident HPV16 infection, the adjusted odds ratio of detecting NPL variants was 6.0 [95% confidence interval (CI), 1.3-27.5)] for nonwhite women or white women who had had nonwhite sex partners compared with white women who had not had nonwhite sex partners. As compared with women who had not used hormonal contraceptives in the 8 months prior to the first HPV16-positive detection, the adjusted odds ratio of detecting NPL variants increased from 1.6 (95% CI, 0.3-9.1) for those who had used hormonal contraceptives for 1-4 months to 5.4 (95% CI, 1.0-28.3) for those who had used hormonal contraceptives for 5-8 months (P for trend = 0.04). There was no difference in HPV16 seroconversion rates between women with prototype-like variants and women with NPL variants. The increased risk for biopsy-confirmed cervical intraepithelial neoplasia grades 2 or 3 associated with detection of incident infection by NPL variants was not explained by differences in persistence between the two variant groups, indicating that biological mechanisms other than viral persistence may be responsible for the observed difference in risk for cervical intraepithelial neoplasia grades 2 or 3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927494

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.

Authors:  Johnnie J Orozco; Joseph J Carter; Laura A Koutsky; Denise A Galloway
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study.

Authors:  Ema Flores-Díaz; Karen A Sereday; Silvaneide Ferreira; Bradley Sirak; João Simão Sobrinho; Maria Luiza Baggio; Lenice Galan; Roberto C Silva; Eduardo Lazcano-Ponce; Anna R Giuliano; Luisa L Villa; Laura Sichero
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

3.  Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle.

Authors:  Walter G Hubert
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.

Authors:  Camille Ragin; Jeffrey C Liu; Gieira Jones; Olubunmi Shoyele; Bukola Sowunmi; Rachel Kennett; Harry J M Groen; Denise Gibbs; Elizabeth Blackman; Michael Esan; Margaret S Brandwein; Karthik Devarajan; Francesco Bussu; Rebecca Chernock; Chih-Yen Chien; Marc A Cohen; El-Mofty Samir; Suzuki Mikio; Gypsyamber D'Souza; Pauline Funchain; Charis Eng; Susanne M Gollin; Angela Hong; Yuh-S Jung; Maximilian Krüger; James Lewis; Patrizia Morbini; Santo Landolfo; Massimo Rittà; Jos Straetmans; Krisztina Szarka; Ruth Tachezy; Francis P Worden; Deborah Nelson; Samuel Gathere; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2016-12-26       Impact factor: 4.944

5.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

6.  Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women.

Authors:  Ann Nielsen; Thomas Iftner; Christian Munk; Susanne K Kjaer
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

Review 7.  Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.

Authors:  Anne F Rositch; Jill Koshiol; Michael G Hudgens; Hilda Razzaghi; Danielle M Backes; Jeanne M Pimenta; Eduardo L Franco; Charles Poole; Jennifer S Smith
Journal:  Int J Cancer       Date:  2012-10-11       Impact factor: 7.396

8.  Acquisition of high-risk human papillomavirus infections and pap smear abnormalities among women in the New Independent States of the Former Soviet Union.

Authors:  Stina Syrjänen; Irena Shabalova; Nicolay Petrovichev; Vladimir Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij Podistov; Galina Chemeris; Larisa Sozaeva; Elena Lipova; Irena Tsidaeva; Olga Ivanchenko; Alla Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila Kljukina; Oksana Erokhina; Marina Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Piero Tosi; Marcella Cintorino; Rosa Santopietro; Kari Syrjänen
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

9.  Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.

Authors:  Helen Trottier; Salaheddin Mahmud; José Carlos M Prado; Joao S Sobrinho; Maria C Costa; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

10.  Genomic differences in the background of different severity in juvenile-onset respiratory papillomatoses associated with human papillomavirus type 11.

Authors:  Tamás Gáll; Andrea Kis; Tímea Zsófia Tatár; Gábor Kardos; Lajos Gergely; Krisztina Szarka
Journal:  Med Microbiol Immunol       Date:  2013-05-07       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.